Get started
Author

Cesar A. Perez

Observed names: C A Perez, C. A. Perez, C. Perez, C.A. Perez, Cesar A Perez, Cesar Augusto Perez, Cesar Perez, Cesar Perez Batista
Observed institutions: University of Central Florida, University of Louisville, University of Miami, SUNY New Paltz, Rosalind Franklin University of Medicine and Science, Sarah Cannon, University of Miami Health System, Cleveland Clinic Florida, Florida Cancer Specialists & Research Institute, Sylvester Comprehensive Cancer Center
ORCID: 0000-0001-5860-4921
Observed ORCID: 0000-0001-5860-4921
OpenAlex ID: A5072305232
Overexpression of the Helix–Loop–Helix protein Id2 blocks T cell development at multiple stages
1999 · Maureen A Morrow, Elizabeth W Mayer, et al. · Molecular Immunology · 139
Overcoming the resistance to Crizotinib in patients with Non-Small Cell Lung Cancer harboring EML4/ALK translocation
2014 · Cesar A. Perez, Michel Velez, et al. · Lung Cancer · 49
Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck
2012 · Cesar A. Perez, Hunho Song, et al. · Oral Oncology · 48
PF-06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study.
2021 · Jordi Rodon Ahnert, Cesar Augusto Perez, et al. · Journal of Clinical Oncology · 47
Distribution of Cervical Lymph Node Metastases From Squamous Cell Carcinoma of the Oropharynx in the Era of Risk Stratification Using Human Papillomavirus and Smoking Status
2016 · Mark J. Amsbaugh, Mehran Yusuf, et al. · International Journal of Radiation Oncology*Biology*Physics · 45
Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA - and HRAS -Dysregulated HNSCC via Convergent Inhibition of mTOR Activity
2023 · Alison E. Smith, Stacia Chan, et al. · Cancer Research · 35
PDF
Primary Mediastinal Large B-Cell Lymphoma during Pregnancy
2012 · Cesar A. Perez, Janki Amin, et al. · Case Reports in Hematology · 32
PDF
Management of immunotherapy toxicities in older adults
2018 · Shruti Bhandari, Amitoj S Gill, et al. · Seminars in Oncology · 31
Cyclical hypofractionated radiotherapy technique for palliative treatment of locally advanced head and neck cancer: institutional experience and review of palliative regimens
2016 · Teresa Finnegan, Joseph Shaughnessy, et al. · The Journal of Community and Supportive Oncology · 30
PDF
Targeting the Met pathway in lung cancer
2012 · Astrid Belalcazar, Daisy Azaña, et al. · Expert Review of Anticancer Therapy · 30
Novel molecular targeted therapies for refractory thyroid cancer
2011 · Cesar A. Perez, Edgardo S. Santos, et al. · Head & Neck · 30
Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly
2018 · Rohit Gosain, Jonathan S. Alexander, et al. · Current Oncology Reports · 25
Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notch mut ).
2022 · Renata Ferrarotto, Robert Metcalf, et al. · Journal of Clinical Oncology · 22
Ethical surgical triage of patients with head and neck cancer during the COVID ‐19 pandemic
2020 · Francisco J. Civantos, Jason M. Leibowitz, et al. · Head & Neck · 22
PDF
Neck dissection for unknown cancer of the head and neck in the era of chemoradiation
2017 · Mark J. Amsbaugh, Mehran Yusuf, et al. · American Journal of Otolaryngology · 21
Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy
2024 · Ari J. Rosenberg, Cesar A. Perez, et al. · American Society of Clinical Oncology Educational Book · 20
PDF
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors
2024 · Benjamin Garmezy, Mitesh J. Borad, et al. · Cancer Research Communications · 20
PDF
660MO First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001)
2023 · C.A. Perez, J.T. Henry, et al. · Annals of Oncology · 20
PDF
Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study.
2024 · Jerome Fayette, Florian Clatot, et al. · Journal of Clinical Oncology · 19
PDF
919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)
2020 · R. Ferrarotto, L.J. Wirth, et al. · Annals of Oncology · 19
BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion ( MTAP -del): Clinical update and first report of pharmacokinetics (PK) and pharmacodynamic (PD) analyses from CA240-0007.
2025 · Kathryn C. Arbour, Ben George, et al. · Journal of Clinical Oncology · 18
PDF
SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001).
2023 · Antoine Hollebecque, Juanita Suzanne Lopez, et al. · Journal of Clinical Oncology · 17
423 Safety and preliminary efficacy of intratumoral cavrotolimod (AST-008), a spherical nucleic acid TLR9 agonist, in combination with pembrolizumab in patients with advanced solid tumors
2020 · Steven O’Day, Cesar Perez, et al. · Regular and Young Investigator Award Abstracts · 16
High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck
2017 · Cesar Augusto Perez, Xiaoyong Wu, et al. · Oral Oncology · 16
Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond
2015 · Cesar A. Perez, Zeyad Hashem Kanaan, et al. · OncoTargets and Therapy · 16
PDF
Works count: 184
Citation count: 1,232
H-index: 19
I10-index: 40
Year
Topic
Type